Markets:

Overview

News

Currencies

International

Treasuries

Unicycive Therapeutics, Inc. - Common Stock (NQ:UNCY)

5.880 -0.350 (-5.62%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 15, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Unicycive Therapeutics, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

The Unmet Need For Innovative And Effective Treatments For Kidney Disease: Acute Kidney Injury

March 07, 2023

By Julian Richard, Benzinga

Via TheNewswire.com

The Unmet Need For Innovative And Effective Treatments For Kidney Disease: Acute Kidney Injury

March 07, 2023

The Unmet Need For Innovative And Effective Treatments For Kidney Disease: Acute Kidney Injury

Via News Direct

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 07, 2023

Via Benzinga

Nasdaq Rises 50 Points; Ciena Earnings Top Expectations ↗

March 06, 2023

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 50 points on Monday. The Dow traded up 0.16% to 33,444.91 while the NASDAQ rose 0.43% to 11,739.11. The S&P...

Via Benzinga

Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

March 06, 2023

Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

March 06, 2023

Via Benzinga

Dow Jumps Over 100 Points; BridgeBio Pharma Shares Spike Higher ↗

March 06, 2023

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Monday. The Dow traded up 0.42% to 33,531.77 while the NASDAQ rose 0.97% to 11,802.73. The S&P 500...

Via Benzinga

Why Unicycive Therapeutics Stock Is Exploding Higher Monday ↗

March 06, 2023

Unicycive Therapeutics Inc (NASDAQ: UNCY) shares are exploding higher Monday after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 06, 2023

Via Benzinga

The Unmet Need For Innovative And Effective Treatments For Kidney Disease: Acute Kidney Injury ↗

March 06, 2023

Unicycive Therapeutics Inc (NASDAQ: UNCY) is a biopharmaceutical company spearheading efforts to develop effective, safe, and novel treatments for kidney disease to improve patient and caregiver...

Via Benzinga

Unicycive: The Company Developing Key Kidney Therapies

February 17, 2023

by\nJohnny Rice, Benzinga Contributor

Via News Direct

Unicycive: The Company Developing Key Kidney Therapies

February 17, 2023

Doug Jermasek, Executive Vice President, Corporate Strategy for Unicycive Therapeutics, Inc. (NASDAQ: UNCY), was recently interviewed by Benzinga.

Via TheNewswire.com

Amarin Posts New Data Showing Benefit of Vascepa In High-Risk Patients With Acute Coronary Syndrome ↗

March 06, 2023

Via Benzinga

Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb

March 06, 2023

From Unicycive Therapeutics, Inc.

Via GlobeNewswire

The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers

March 03, 2023

By Julian Richard, Benzinga

Via TheNewswire.com

The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers

March 03, 2023

The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers

Via News Direct

The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers ↗

March 02, 2023

Unicycive Therapeutics Inc (NASDAQ: UNCY) is a biopharmaceutical company committed to developing effective and safe treatments for kidney (renal) disease to reduce death rates and improve patients and...

Via Benzinga

Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings

February 27, 2023

From Unicycive Therapeutics, Inc.

Via GlobeNewswire

Unicycive: The Company Developing Key Kidney Therapies ↗

February 16, 2023

Doug Jermasek, Executive Vice President, Corporate Strategy for Unicycive Therapeutics, Inc. (NASDAQ: UNCY), was recently interviewed by Benzinga.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

February 10, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

February 07, 2023

Via Benzinga

Unicycive: This Biotech Company Receives Promising Results From New Trial

February 06, 2023

Unicycive: This Biotech Company Receives Promising Results From New Trial

Via News Direct

Unicycive: This Biotech Company Receives Promising Results From New Trial ↗

February 03, 2023

Unicycive Therapeutics Inc. (NASDAQ: UNCY) is a biotechnology company developing drug candidates currently focused on kidney disease. The innovative treatments may have vast potential outside of the...

Via Benzinga

Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea

February 02, 2023

From Unicycive Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

January 26, 2023

Via Benzinga

Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation’s Spring Clinical Meetings

January 23, 2023

Data support UNI-494’s potential to treat acute kidney disease and underscore the phosphate binding benefits of Renazorb as a potential treatment for hyperphosphatemia

From Unicycive Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

January 06, 2023

Via Benzinga

Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023

January 05, 2023

Growing body of clinical evidence support the potential of Renazorb and UNI-494 to effectively treat hyperphosphatemia and acute kidney disease, respectively

From Unicycive Therapeutics, Inc.

Via GlobeNewswire

Why Tesla Shares Are Trading Lower; Here Are 32 Stocks Moving Premarket ↗

January 03, 2023

Gainers

Via Benzinga

Why Silo Pharma Shares Are Trading Higher By Around 64%? Here Are 46 Stocks Moving In Friday's Mid-Day Session ↗

December 30, 2022

Gainers Dermata Therapeutics, Inc. (NASDAQ: DRMA) shares jumped 121% to $0.4428 after the company requested to withdraw its registration on Form S-1 and said it does not intend to pursue the...

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Unicycive Therapeutics, Inc. - Common Stock (NQ:UNCY)

All News about Unicycive Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today